ALKBH5 and melanoma: ALKBH5 overexpression induces immunosuppressive TME and promotes immune evasion in multiple cancers, including ICC [132], melanoma [133], colorectal carcinoma [133] and glioblastoma multiforme [134], suggesting that ALKBH5 could affect tumor response to immunotherapy.